about
Macrocyclic histone deacetylase inhibitorsPotential use of histone deacetylase inhibitors in cancer therapyEpigenomics of leukemia: from mechanisms to therapeutic applicationsA perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, nrf2, and epigenomicsCutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementTrial Watch: Proteasomal inhibitors for anticancer therapyGene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancerThe HDAC inhibitor FK228 enhances adenoviral transgene expression by a transduction-independent mechanism but does not increase adenovirus replicationAnticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivoHDAC inhibition induces increased choline uptake and elevated phosphocholine levels in MCF7 breast cancer cellsHistone acetylation-mediated regulation of the Hippo pathwayPanobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cellsInhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphomaPanobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyAuto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survivalProlonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse modelPhase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.ChromoHub: a data hub for navigators of chromatin-mediated signallingInterferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity.Finding Inspiration in the Protein Data Bank to Chemically Antagonize Readers of the Histone Code.Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesisRomidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumorsA phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumorsA phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Polycomb target genes are silenced in multiple myeloma.Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activityHistone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivoDruggability of methyl-lysine binding sites.
P2860
Q24629065-B867AE99-C626-4828-9DF0-AB5C7FE54E08Q26769594-D5675DCC-5828-438C-A2B1-E5C890D2A0DAQ26823403-8D39EDAD-FD2E-4A76-89DF-17F19784C07DQ26852571-4325882E-54B5-4300-9A4C-0DC865EDAC43Q27024076-AB646066-2006-406D-A860-09D4C928ED04Q28082910-51B57612-F7DF-4E4E-8620-293AF371EE9DQ28477038-C34E40DA-4F19-4F75-98CB-9093BA6EBD9FQ28477188-3CEA6C56-6538-4985-A655-52BCC139EB67Q28482468-848E43D5-5035-495C-B131-F8DAF717B607Q28486529-53C18C82-10CC-4EA0-A000-0D2D08403981Q28487649-8EB3A6E8-EC50-434D-9AF5-DD9D71C42B69Q28533896-57C4BA61-7D6E-410A-9F51-213A0A255BE0Q28534761-1EA9C0D6-DF76-4CEA-8663-056D85D76F5EQ28535006-8B1CC406-4E4E-418C-8F86-38AFDD789A33Q28544949-5DD01A16-5B77-453B-A80C-3C254529F084Q28577251-0CB4B1CD-069A-4884-864D-173B8F731BEFQ28743986-B4FE8451-400C-4E65-9F06-B421E9390740Q30416647-6D839DC5-1623-40A1-89E1-3B90CEE9E59DQ30485542-C777A780-0E78-4437-9AA7-E9CE31B505F4Q31101656-DFDEA4ED-2D6C-47C8-A4C6-377EB3B863F5Q31117873-DC6F9DBD-953F-40F9-BAC6-B21BBD89C367Q33390343-89F1D5C1-6EF5-40BE-A34B-281037D83C69Q33390876-AF7E0020-BF57-4BFA-8EFA-0120DB77833DQ33394324-A86BFB7B-DAC4-4D8A-9C35-188A33FDEB91Q33394863-E2A5201A-ECCD-410A-B110-49FE32B07839Q33398014-45FB3787-1051-4321-8ED5-3CB829661FBBQ33402040-197DACF2-1E53-47E1-891D-4ACCF64072CFQ33402619-4B66AA65-85BB-4876-974E-D59989CBF752Q33408198-E5B0946F-65F3-46E8-AC10-ED49E371A14AQ33410544-3A763543-3ADF-4B36-8B73-152D7BB75B6CQ33410997-8E1DDEC2-7D89-434B-9E0D-44F6ED5BAA2EQ33415594-3705BF63-4D69-4082-96ED-9FBE850D77D1Q33439519-0E4EEFD5-F91F-412A-BCCC-0FAEF090A76EQ33622342-3D177C88-2AB5-42C4-8AAD-AC5CA81DC9C2Q33633898-9983DDA2-A24E-4709-8E51-060919573C2CQ33649465-E67F7DAB-3FB9-4A68-9E1D-874EC7C3529AQ33705588-E6B89E3E-1396-41AD-816E-08986D7F6CBCQ33731197-4D05653A-96F5-4F51-B41F-9CBABAACC3BCQ33927370-2A458B98-FB61-4A42-A579-D72CF4B4A957Q34093054-E6DC0C94-D1D6-4CD5-B258-7CDD2E388FBD
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical studies of histone deacetylase inhibitors.
@en
Clinical studies of histone deacetylase inhibitors.
@nl
type
label
Clinical studies of histone deacetylase inhibitors.
@en
Clinical studies of histone deacetylase inhibitors.
@nl
prefLabel
Clinical studies of histone deacetylase inhibitors.
@en
Clinical studies of histone deacetylase inhibitors.
@nl
P1476
Clinical studies of histone deacetylase inhibitors
@en
P2093
H Miles Prince
P304
P356
10.1158/1078-0432.CCR-08-2785
P407
P577
2009-06-09T00:00:00Z